OM

Omnicell IncNASDAQ OMCL Stock Report

Last reporting period 30 Jun, 2024

Updated 19 Sep, 2024

Last price

Market cap $B

2.066

Small

Exchange

XNAS - Nasdaq

OMCL Stock Analysis

OM

Uncovered

Omnicell Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

19/100

Low score

Market cap $B

2.066

Dividend yield

Shares outstanding

44.988 B

Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. The company is headquartered in Santa Clara, California and currently employs 4,230 full-time employees. The company went IPO on 2001-08-08. The firm is focused on transforming the pharmacy care delivery model through automation designed to replace manual, error-prone processes, combined with a single, cloud-based platform and advanced services offerings. The firm's point-of-care automation solutions are designed to improve clinician workflows in patient care areas of the healthcare system, such as nursing units, patient wards, operating rooms, and emergency departments. The firm's Omnicell Interface Software provides interface and integration between its medication-use products or its supply products and a healthcare facility's in-house information management systems. The firm's Central Pharmacy IV Compounding Service offers a range of service model inclusive of IV robotic technology, data analytic tools, and clinical support for insourced sterile compounding programs.

View Section: Eyestock Rating